New research has highlighted the effectiveness of long-term treatment with tamoxifen, the first targeted therapy to be approved for treatment of breast cancer, for many patients with the disease. Stephen Edge, MD, formerly of RPCI and Alfiero Foundation Endowed Chair in Breast Oncology, and Gokul Das, PhD, Co-Director of RPCI's Breast Disease Site Research Group, discuss these recent findings as well as their ongoing clinical study, still recruiting new patients, to determine which patients will respond best to this important endocrine therapy.
Tamoxifen Therapy for Breast Cancer with Drs. Stephen Edge and Gokul Das
Sunday, February 10, 2013